Preventing Parenteral Nutrition-Associated Liver Disease in Children
46 Questions
1 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the incidence of short bowel syndrome in neonates?

  • 37.5 per 100,000 live births
  • 10.0 per 100,000 live births
  • 24.5 per 100,000 live births (correct)
  • 50.0 per 100,000 live births
  • What percentage of patients with intestinal failure will develop PNALD?

  • Three-quarters
  • All patients
  • One-third
  • Two-thirds (correct)
  • What is the case fatality rate of short bowel syndrome in neonates?

  • 37.5% (correct)
  • 25.0%
  • 75.0%
  • 50.0%
  • What is the purpose of this clinical guideline?

    <p>To develop recommendations for the care of children with PN-dependent intestinal failure</p> Signup and view all the answers

    What is the name of the working group that developed the concepts used to evaluate the evidence in this guideline?

    <p>The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) Working Group</p> Signup and view all the answers

    How many questions were used to develop the recommendations in this guideline?

    <p>4</p> Signup and view all the answers

    What is the term used to describe PNALD in this guideline?

    <p>Parenteral nutrition–associated liver disease (PNALD)</p> Signup and view all the answers

    What percentage of patients with PNALD traditionally progress to end-stage liver disease?

    <p>25%</p> Signup and view all the answers

    What percentage of long-term survival does PNALD have?

    <p>70%–90%</p> Signup and view all the answers

    What is the nature of PNALD?

    <p>Cholestatic</p> Signup and view all the answers

    What is the primary reason for using liver biopsies as endpoints?

    <p>To depict a picture of cholestasis and varying degrees of fibrosis</p> Signup and view all the answers

    What type of fatty acids are predominantly found in soy-based fat emulsions?

    <p>ω-6 long-chain polyunsaturated fatty acids</p> Signup and view all the answers

    What is a risk factor for PNALD in premature babies?

    <p>Imature livers with incompletely expressed enzymatic activity</p> Signup and view all the answers

    What is the effect of endotoxin on bile transport proteins?

    <p>It impairs bile transport proteins</p> Signup and view all the answers

    What is the goal of therapy in patients with PNALD?

    <p>To optimize intestinal function and promote gut adaptation</p> Signup and view all the answers

    What is a common complication in patients with PN-dependent intestinal failure?

    <p>Catheter-related bloodstream infection (CLABSI)</p> Signup and view all the answers

    What is the consequence of frequent CLABSIs in patients with PNALD?

    <p>Increased risk of PNALD</p> Signup and view all the answers

    Why are children with intestinal failure at risk of CLABSIs?

    <p>They have feeding enterostomies, stomas, and overgrowth of intestinal bacteria</p> Signup and view all the answers

    What is the primary objective of instilling 70% ethanol as a lock solution into the PN catheter?

    <p>To prevent CLABSI and reduce catheter replacements</p> Signup and view all the answers

    What is the minimum concentration of ethanol required to penetrate and break down biofilm in laboratory studies?

    <p>30%</p> Signup and view all the answers

    What is the recommended dwell time for 70% ethanol lock solution to be effective in vivo?

    <p>2 hours</p> Signup and view all the answers

    What type of catheters have been tested with ethanol lock therapy in children?

    <p>Only silicone</p> Signup and view all the answers

    What is the association between IV SOE and PNALD in mixed adult and pediatric home PN cohorts?

    <p>Positive association</p> Signup and view all the answers

    What is the purpose of adding fish oil emulsion (FOE) to the treatment of children with HPN who develop PNALD?

    <p>To reduce the dose of SOE</p> Signup and view all the answers

    What is the primary mechanism of ursodeoxycholic acid (UDCA) in treating cholestatic liver disease?

    <p>Correcting bile acid deficiency and improving bile flow</p> Signup and view all the answers

    What is the purpose of multidisciplinary nutrition support teams or intestinal rehabilitation programs in children with intestinal failure?

    <p>To optimize the management of children with intestinal failure who require HPN</p> Signup and view all the answers

    What is the frequency of planned revisions for this clinical guideline?

    <p>In 2018</p> Signup and view all the answers

    What is the recommendation grade for the use of ethanol lock to prevent CLABSI and reduce catheter replacements in children at risk of PNALD?

    <p>Weak</p> Signup and view all the answers

    What is the recommended dose of SOE to treat cholestasis in children with PNALD?

    <p>≤1 g/kg/d</p> Signup and view all the answers

    What is the status of FOE in the United States?

    <p>Available under a compassionate use protocol</p> Signup and view all the answers

    What is the primary outcome of RCTs studying SMOF in preterm infants?

    <p>Plasma phospholipid profiles and adverse events</p> Signup and view all the answers

    What is the current status of fat emulsions containing a blend of refined olive and soybean oil for use in pediatric patients?

    <p>Approved for use in adult patients receiving PN</p> Signup and view all the answers

    What is the recommended treatment for elevated liver enzymes in children with PNALD?

    <p>Enteral UDCA</p> Signup and view all the answers

    What is the concern with restricting lipids in pediatric patients with PNALD?

    <p>Poor growth and development</p> Signup and view all the answers

    What is the benefit of managing patients with PNALD by a multidisciplinary intestinal rehabilitation team?

    <p>Improved PNALD outcomes</p> Signup and view all the answers

    What is the limitation of the studies on UDCA for the treatment of PNALD?

    <p>Confounded by concurrent lipid dose reduction and advancement of enteral feedings</p> Signup and view all the answers

    What is the current recommendation for the use of SMOF in pediatric patients with PNALD?

    <p>No recommendation can be made</p> Signup and view all the answers

    What is the grading of the recommendation for the use of UDCA in pediatric patients with PNALD?

    <p>Weak</p> Signup and view all the answers

    What is the quality of the evidence supporting the recommendation to refer patients with PN-dependent intestinal failure to multidisciplinary intestinal rehabilitation programs?

    <p>Very low</p> Signup and view all the answers

    What is the primary reason for the weak recommendation to refer patients with PN-dependent intestinal failure to multidisciplinary intestinal rehabilitation programs?

    <p>The evidence is of very low quality</p> Signup and view all the answers

    What is the main limitation of the studies comparing clinical outcomes before and after the establishment of multidisciplinary intestinal rehabilitation programs?

    <p>Historical controls</p> Signup and view all the answers

    What is the relative risk of survival from intestinal failure in patients treated with multidisciplinary intestinal rehabilitation programs compared to historical controls?

    <p>1.22 (95% CI, 1.06-1.40)</p> Signup and view all the answers

    What is the main reason for the heterogeneity of patient populations in the studies on multidisciplinary intestinal rehabilitation programs?

    <p>All of the above</p> Signup and view all the answers

    What is the primary improvement needed in the literature on multidisciplinary intestinal rehabilitation programs?

    <p>Consensus on definitions of key clinical outcomes</p> Signup and view all the answers

    What is the likely impact of further research on the recommendation to refer patients with PN-dependent intestinal failure to multidisciplinary intestinal rehabilitation programs?

    <p>Further research is likely to change this recommendation</p> Signup and view all the answers

    What is the primary outcome of interest in the meta-analysis by Stanger et al?

    <p>Survival from intestinal failure</p> Signup and view all the answers

    Study Notes

    Parenteral Nutrition-Associated Liver Disease (PNALD)

    • PNALD is a life-threatening complication associated with parenteral nutrition (PN) dependence.
    • Incidence of short bowel syndrome in neonates: 24.5 per 100,000 live births with a case fatality rate of 37.5%.
    • Two-thirds of patients with intestinal failure will develop PNALD.
    • Prevention of PNALD can improve the quality of life of children and their families.

    Characteristics of PNALD

    • Cholestatic in nature with a spectrum of disease, ranging from mild cholestasis to cirrhosis and liver failure.
    • No standardized definition of PNALD, but often described by hyperbilirubinemia (direct or total).
    • Liver biopsy is invasive and not practical for routine care, and is prone to sampling error.

    Risk Factors of PNALD

    • Premature babies have an increased risk for PNALD due to immature livers with incompletely expressed enzymatic activity.
    • Recurrent sepsis increases the risk of cholestasis.
    • Lack of enteral feeding impairs the enterohepatic circulation and bile acid secretion/absorption, leading to mucosal atrophy and bacterial translocation.
    • CLABSIs are associated with an increased risk of PNALD when they occur frequently.
    • The instillation of 70% ethanol as a lock solution into the PN catheter has been examined as a strategy to prevent CLABSI.

    Fat Emulsion Strategies

    • High doses of soy-based fat emulsions (SOEs) may promote cholestasis.
    • Reduced doses of SOEs, addition of fish oil emulsion (FOE), and fat emulsions designed with a mixture of soy oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) have been considered as potential therapies in children with PN-dependent intestinal failure.

    Ursodeoxycholic Acid (UDCA)

    • UDCA is a bile acid that has been given orally to treat cholestatic liver disease in adults.
    • The mechanism of UDCA's effects is not fully established, but may correct bile acid deficiency, improve bile flow, displace cytotoxic bile acids, or provide immunomodulatory protection.

    Multidisciplinary Intestinal Rehabilitation Team

    • Multidisciplinary nutrition support teams or intestinal rehabilitation programs have been developed to optimize the management of children with intestinal failure who require HPN.
    • The impact of these programs on PNALD outcomes has been examined, with studies suggesting improved survival and clinical outcomes.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    This quiz covers clinical guidelines for the care of children with intestinal failure dependent on parenteral nutrition, focusing on preventing or treating parenteral nutrition-associated liver disease. It's based on a systematic review of the best available evidence.

    More Like This

    Parenteral nutrition
    38 questions

    Parenteral nutrition

    DelightfulPink avatar
    DelightfulPink
    Parenteral Nutrition Components Quiz
    15 questions
    Parenteral Nutrition Administration
    18 questions
    Parenteral Nutrition (PN) Therapy
    174 questions
    Use Quizgecko on...
    Browser
    Browser